Key Advisors & Corporate Counsel
Jodie Currie
Sales & Marketing Consultant
Jodie Currie has over 20 years of strategic healthcare
management experience with both large and st
art up companies. She has
extensive experience in bringing new technology to market including biotech,
surgical and service products. Her areas of expertise include strategic
business development, new product development, clinical
trials and
marketing/sales. She has worked with Bristol Myers Squibb, Medtronic,
Curative Health Services, Smith & Nephew and MedEfficiency.
Sheri Dimond
Consultant
Sheri Dimond has over 13 years of clinical experience
with Nitric Oxide. Her background is in Pulmonary Medicine and more
recently the Wound Care arena. Sheri has been the Clinical Manager at
PulmoNOx Medical Inc. since 1998 where she has played an important role in
successfully bringing two novel innovations to the international market.
Her broad experience includes; pre-design research, product development,
marketing and product distribution, with major contributions involving the
management of a distribution network, implementing a complaint management
system, and creating training programs for end users. Sheri prides herself
in her involvement in the research proceeding in the area of nitric oxide.
She has executed numerous pilot trials and has participated in the
development and implementation of a number of study protocols.
Peggy Dotson, RN
Reimbursement Consultant
Peggy Dotson began her career as a critical care nurse
(9 years) then transitioned into the healthcare medical device industry with
Bristol-Myers Squibb (23 years) in varying roles including sales, marketing,
business development, worldwide market planning and reimbursement. In 2003,
Peggy started her own business, Healthcare Reimbursement Strategy,
which evaluates healthcare policy, coverage and reimbursement and related
market issues. She provides insight on the dynamics of the healthcare system
and develops the most advantageous strategy to obtain coverage, coding and
payment for products and services. She identifies opportunities or gaps in
the available and future evidence-based data to enhance strategic product
development and / or to accelerate market entry. Her affiliations include;
board member of the National Association of Subacute and Post Acute Care
(NASPAC) since 1998, member of the Government & Regulatory Public Policy
Task Force, Association for the Advancement of Wound Care (AAWC) since 2002,
past member of the Medicare Payment Policy Working Group (AdvaMed), and
member of the Women Business Leaders in Healthcare (WBL) since 2001. She
helped co-found the Coalition of Wound Care Manufacturers (CWCM) and
functioned as Co-Chair from 1999 to through mid 2003.
Michel H. E. Hermans, MD
Consultant Medical & Clinical Affairs
Michel H.E. Hermans is an M.D. with extensive experience in general surgery, burn care and general wound care. He has more than 18 years of experience in the Medical Device and Pharmaceutical Industry, where he has held several Medical Director jobs, several with global responsibilities.
He has vast experience in all aspects of clinical trialing, medical marketing and medical education. He has published more than 100 articles and is author, editor or co-editor of a number of chapters in books and supplements to Journals. He has given more than 450 lectures, mainly on different aspects of wound care, in all regions of the world. He currently owns a consulting company.
Chris Miller, PhD, BA RRT
Consultant
Dr. Chris Miller is a part time Research Associate in the Division of Infectious Diseases at the University of British Columbia, Canada. Dr. Miller has established himself as a pioneer in nitric oxide technology and therapeutic research. He was the visionary founder of Pulmonox Research and Development Corporation (1993) based on nitric oxide gas as a platform technology. For nearly a decade he was the CEO of Pulmonox Medical Inc. a highly successful leading-edge biotech company. He continues to consult for biopharmaceutical companies dedicated to the development of nitric oxide therapies and technologies in the areas of immunology, cancer and infectious diseases.
Dr. Miller has a doctorate in experimental medicine and degrees in Health Management and Respiratory Therapy. His thesis research evaluated the use of gaseous nitric oxide (gNO) as antibacterial agent for respiratory tract infections and surface wound infections. Dr. Miller, has authored over 20 papers in peer review publications and has five issued patents with 14 pending. He is soon to be appointed as an Associate Clinical Professor in the Faculty of Medicine at his alma mater. In 2004, he received the prestigious Jimmy Schultz Award for his “dedication to improving patient care through research and innovative use of respiratory care technology.”
Bruce Murray
Consultant
Bruce R. Murray, BSc, is one of the founders of Pulmonox Medical, Nitric Biotherapeutics' strategic partner and is currently President of Geonox Corporation. He has more than 25 years experience with medical and industrial gases and directed the development of a unique process for the production of high purity nitric oxide gas for medical use. He is co-author of several patents related to therapies and devices for human and veterinary use of nitric oxide gas.
Alex Stenzler
Consultant
Alex Stenzler is the Vice President of Advanced Technologies for VIASYS Respiratory Care Inc, a subsidiary of VIASYS Healthcare Corporation (NYSE-VAS) where he has worked since 1991. Mr. Stenzler brings more than thirty years of clinical and commercial experience in pulmonary medicine to his position. He started his career in the medical field as an Air Force aeromedical evacuation specialist during the Vietnam War and migrated into respiratory medicine as a Respiratory Therapist. Prior to joining VIASYS Respiratory Care, he was President of a respiratory research and development firm in New York and had directed Pulmonary Physiology Laboratories and Respiratory Care Departments in New York and Florida. Mr. Stenzler has been the principal investigator for two NIH studies and has served on the steering committees for randomized controlled trials in High Frequency Ventilation, Inhaled Nitric Oxide and Liquid Ventilation. Much of the research efforts that he has lead have been targeted at reducing the mortality and morbidity of premature infants and young children. Born and raised in New York City, Mr. Stenzler has also held several academic appointments, including Assistant Professor at the State University of New York at Stonybrook and twelve years in the Graduate School of Adelphi University. He did his undergraduate work at Queens College (City University of New York), has published numerous papers and abstracts and has been an invited speaker at many national and international congresses. He also holds more than a dozen US patents for various technologies.
Bary Sugarman, BS Engr
Consultant
President of Diverstech, a product development and
Regulatory Affairs company. Former pharmaceutical manufacturer CEO with 29
years experience in pharmaceutical product development, manufacturing,
management, and regulatory affairs. Strong history in Nitric Oxide
production, SOPs, and government approvals.
Kim Voth, RN
Clinical Consultant
Kim is a healthcare veteran with a vast clinical
experiential background including inpatient, outpatient, and home health.
She has been involved in wound care since 1991, developing and bringing on-
line more than 100 wound programs in the United States and Puerto Rico.
Samplings of her multifaceted responsibilities in wound care are VP of
Operations and Clinical Development, Senior Manager of Medical Services, and
Regional Director of Clinical Services. She has participated on numerous
national wound conference planning committees and is a frequent national
speaker on a variety of topics.
Susan Carta Prudhoe, MSCE
Consultant
Susan has a master’s degree in Chemical Engineering and 16 years experience working in R & D and Clinical Research. With 13 years experience monitoring clinical trials, Susan has worked with numerous Pharmaceutical and Medical Device companies, including Wyeth, Hoffmann-La Roche, Genta, Astellas Pharma, Johnson and Johnson, Schering-Plough, Smith & Nephew, Kendall, and Procter & Gamble. She has extensive experience designing clinical trial protocols, selecting clinical research sites, training research staff, managing research sites, implementing patient enrollment strategies, and ensuring the successful transmission of quality data for submission to the FDA. She is knowledgeable in FDA regulations, and has the opportunity to train with several FDA auditors.
Michael Harrington, Esq
Corporate Counsel
